• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BTG touts use of radiopaque drug-eluting bead

January 28, 2019 By Sarah Faulkner

BTG's Interventional Oncology LogoBTG (LON:BTG) said this month that an Australian patient was treated with its radiopaque drug-eluting bead.

The DC Bead Lumi product is the first commercial drug-eluting bead that can be loaded with doxorubicin or irinotecan to treat tumors in patients with hepatocellular carcinoma and liver metastases from colorectal cancer, according to BTG.

The beads’ radiopacity enable physicians to monitor where the beads are placed in the tumor, aiding in localized drug delivery.

The DC Bead Lumi, which won CE Mark clearance in March of 2017, was used at Wesley Hospital to perform transarterial chemoembolization on a patient with liver tumors, BTG reported.

“Feedback from both physicians and their patients indicate that DC Bead Lumi is an important advance in personalised, loco-regional cancer therapy,” Dr. Anthony Wilkinson, BTG’s regional medical director, said in prepared remarks.

“As a leader in intra-hepatic therapy for HCC, BTG is excited to be able to launch our latest drug-eluting bead product in the Australian market. We anticipate that the enhanced visualization of DC Bead Lumi will lead to improved patient outcomes through more accurate delivery,” Wilkinson added.

Last year, Boston Scientific (NYSE:BSX) announced that it would spend $4.24 billion to acquire BTG and its portfolio of interventional drug-device therapies.

The Marlborough, Mass.-based company said that its acquisition of BTG would augment Boston Scientific’s capabilities in the treatment of cancer and pulmonary embolism.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: BTG

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS